[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-357235-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-357235-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identication-design-and-in-vivo-proof-of-concept-of-a-shared-apc-neoantigen-delivered-via-a-self-amplifying-rna-containing-virus-like-nanoparticle-for-cancer-vaccination","Identiﬁcation, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination","","Colorectal cancer remains a major cause of mortality, with over 80% of cases linked to mutations in the Adenomatous Polyposis Coli (APC) tumor suppressor gene. Familial Adenomatous Polyposis (FAP) is an inherited condition that progresses to colorectal cancer with near-complete lifetime risk. This study used bioinformatics to identify shared neoantigen epitopes within the APC mutational cluster region, then engineered and optimized an APC-mutant-inserted chimeric virus-like particle carrying a self-amplifying RNA replicon. In vitro assays showed T-cell activation and restimulation, and BALB/c mouse experiments demonstrated neoantigen-specific IgG responses, supporting APC-associated CRC vaccine proof of concept.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identication-design-and-in-vivo-proof-of-concept-of-a-shared-apc-neoantigen-delivered-via-a-self-amplifying-rna-containing-virus-like-nanoparticle-for-cancer-vaccination/357235/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identication-design-and-in-vivo-proof-of-concept-of-a-shared-apc-neoantigen-delivered-via-a-self-amplifying-rna-containing-virus-like-nanoparticle-for-cancer-vaccination/357235.png","ImageObject",300,407,{"name":42,"@type":43},"Jasmine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What neoantigens were targeted in this study?","Question",{"text":63,"@type":64},"The study identified shared neoantigen epitopes present in the APC gene mutational cluster region (MCR), where FAP-associated mutations are typically observed.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the cancer vaccine platform engineered?",{"text":68,"@type":64},"A chimeric virus-like particle (VLP) was developed to encapsulate a self-amplifying RNA (saRNA) replicon encoding a neoantigen construct with identified mutated APC sequences inserted into a WT APC backbone.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports in vivo immune activity?",{"text":72,"@type":64},"Serum from intramuscularly dosed BALB/c mice showed significant neoantigen-specific IgG titers versus vehicle and WT APC control mice, confirming VLP expression of neoantigens and neoantigen-specific immune activity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},357235,1790153068,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","TYPE Brief Research Report PUBLISHED 04 June 2026  \nDOI 10.3389/fimmu.2026.1810178  \nOPEN ACCESS  \nEDITED BY  \nAna Maria Waaga-Gasser,  \nHarvard Medical School, United States  \nREVIEWED BY  \nZongde Zhang,  \nSouthwest Medical University, China Sibapriya Chaudhuri,  \nUniversity of California, San Francisco, United States  \n*CORRESPONDENCE  \nAlfred J. Simmons  \n[AJS@chimeron.com](AJS@chimeron.com)[ ](AJS@chimeron.com)Satish Adhikari  \n [satish.adhikari@chimeron.com](satish.adhikari@chimeron.com)[ ](satish.adhikari@chimeron.com)RECEIVED 12 February 2026 REVISED 24 April 2026 ACCEPTED 19 May 2026 PUBLISHED 04 June 2026  \nCITATION  \nSimmons AJ, Nikonova AS, Jonas CD, Pniewski KA, Upreti D, Perez MI and Adhikari S (2026) Identiﬁcation, design, and in vivo proof of concept of a shared APC neoantigen delivered via a selfamplifying RNA containing virus-like nanoparticle for cancer vaccination. Front. Immunol. 17:1810178 .  \ndoi: 10.3389/fimmu.2026.1810178  \nCOPYRIGHT  \n© 2026 Simmons, Nikonova, Jonas, Pniewski, Upreti, Perez and Adhikari. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nIdentiﬁcation, design, and in vivo proof of concept of a shared APC neoantigen delivered  \nvia a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination  \nAlfred J. Simmons 1,2*, Anna S. Nikonova 1, Chloe D. Jonas 1, Katherine A. Pniewski 1, Deepak Upreti 1, Maria I. Perez 1 and Satish Adhikari 1*  \n1Chimeron Bio Corporation, Philadelphia, PA, United States, 2 Nanotherapeutics Research Laboratory, Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, United States  \nColorectal Cancer (CRC) accounts for the second highest number of cancerrelated mortalities rate worldwide, and its incidence and mortality is expected to continue to increase in the coming years. Over 80% of CRC cases are caused by mutation in the Adenomatous Polyposis Coli (APC) gene, a tumor suppressor gene involved in the Wnt signaling pathway that prevents uncontrolled cell growth. Familial Adenomatous Polyposis (FAP) is a rare, inherited, pediatric disorder characterized by the development of countless adenomatous (benign) polyps in the colon and/or rectum, and over the patient’s lifetime there is an almost 100% likelihood that the disorder will progress into CRC. In this study, we utilized bioinformatics to identify shared neoantigen epitopes present at the mutational cluster region (MCR) of the APC gene of multiple CRC patients, where FAP-associated mutation is typically observed. We then developed and optimized a chimeric virus-like particle (VLP) to encapsulate an saRNA replicon encoding a neoantigen construct featuring the identiﬁed mutated APC sequences inserted into a WT APC backbone. T-cell speciﬁc activation and restimulation against neoantigen peptide fragments were observed in vitro, indicating the capacity for a T-cell mediated response in vivo. Serum samples from intramuscularly-dosed BALB/c mice exhibited signiﬁcant neoantigen-speciﬁc IgG titers compared against vehicle control and WT APC control mice, conﬁrming VLPexpression of neoantigens and indicating neoantigen-speciﬁc in vivo immune activity. The signiﬁcant response observed against the nanoparticle-expressed APC neoantigen serves as proof-of-concept for a saRNA-expressed cancer vaccine against APC-associated CRC.  \nKEYWORDS  \nadenomatous polyposis coli, cancer vaccine, colorectal cancer, familial adenomatous polyposis, self-amplifying RNA, virus-like nanoparticle  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nC","cbCaiaJwBqDjpqlP","https://ap.wps.com/l/cbCaiaJwBqDjpqlP","pdf",1099065,"English","# Introduction\n## Rationale: Wnt pathway and APC mutations in CRC and FAP\n## Frameshift APC mutations and vaccine targeting concept","[{\"question\":\"What neoantigens were targeted in this study?\",\"answer\":\"The study identified shared neoantigen epitopes present in the APC gene mutational cluster region (MCR), where FAP-associated mutations are typically observed.\"},{\"question\":\"How was the cancer vaccine platform engineered?\",\"answer\":\"A chimeric virus-like particle (VLP) was developed to encapsulate a self-amplifying RNA (saRNA) replicon encoding a neoantigen construct with identified mutated APC sequences inserted into a WT APC backbone.\"},{\"question\":\"What evidence supports in vivo immune activity?\",\"answer\":\"Serum from intramuscularly dosed BALB/c mice showed significant neoantigen-specific IgG titers versus vehicle and WT APC control mice, confirming VLP expression of neoantigens and neoantigen-specific immune activity.\"}]","Identiﬁcation, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination | PDF",1790129420,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa28ed0534679abd4d068febc8555a40.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2bd8ea854b71c8d292445eb456d9538.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35df70369c12bc0c2f49f4e5ae0c7fb2.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/251a529d0b0d714f4682ebfb4b9d782e.webp",980,1385]